Myocarditis associated with Covid-19 disease: A systematic review of published case reports and case series.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
11
05
2021
received:
25
01
2021
accepted:
24
05
2021
pubmed:
9
7
2021
medline:
25
2
2023
entrez:
8
7
2021
Statut:
ppublish
Résumé
Covid-19 is an extremely contagious illness caused by the severe acute respiratory syndrome (SARS-CoV-2) virus. The cardiac involvement in such a public health emergency disease has not been well studied and a conflicting evidence exists on this issue. This systematic review article aimed to compile and illustrate clinical characteristics, diagnostic findings, management, and outcomes manifesting in myocarditis linked with Covid-19. A literature search was accomplished for published eligible articles with MEDLINE/PubMed and Embase databases. All eligible case reports and case series were included from around the world without any language restrictions. For this review, inclusion criteria were laboratory-confirmed SARS-CoV-2 infection cases reporting a diagnosis of acute myocarditis. Data from 41 studies describing myocarditis in 42 Covid-19 patients was obtained. The median age of these patients was 43.4 years, with 71.4% of them being men. Fever was the most prevalent presenting symptoms seen in 57% of patients. Hypertension was the most pervasive comorbidity accompanying these patients. Cardiac biomarkers troponin and brain natriuretic peptide (BNP) were raised in almost 90% and 87% of patients, respectively. Electrocardiogram findings were nonspecific and included ST-segment and T-wave changes. Echocardiogram commonly showed left ventricular systolic dysfunction with increased heart size. Cardiac magnetic resonance imaging (CMRI) exhibited myocardial edema and injury. The most prevalent histopathological feature appreciated was diffuse lymphocytic inflammatory infiltrates. Antivirals and corticosteroids were the most frequently used medications. About 38% of patients also needed vasopressor assistance. Out of 42 patients, 67% recovered, and eight died. Because of the risk of a sudden worsening of patients conditions and myocarditis association with considerable mortality and morbidity, a knowledge of this cardiac complication of Covid-19 disease is crucial for healthcare professionals.
Sections du résumé
BACKGROUND
BACKGROUND
Covid-19 is an extremely contagious illness caused by the severe acute respiratory syndrome (SARS-CoV-2) virus. The cardiac involvement in such a public health emergency disease has not been well studied and a conflicting evidence exists on this issue.
OBJECTIVE
OBJECTIVE
This systematic review article aimed to compile and illustrate clinical characteristics, diagnostic findings, management, and outcomes manifesting in myocarditis linked with Covid-19.
METHODS
METHODS
A literature search was accomplished for published eligible articles with MEDLINE/PubMed and Embase databases. All eligible case reports and case series were included from around the world without any language restrictions. For this review, inclusion criteria were laboratory-confirmed SARS-CoV-2 infection cases reporting a diagnosis of acute myocarditis.
RESULTS
RESULTS
Data from 41 studies describing myocarditis in 42 Covid-19 patients was obtained. The median age of these patients was 43.4 years, with 71.4% of them being men. Fever was the most prevalent presenting symptoms seen in 57% of patients. Hypertension was the most pervasive comorbidity accompanying these patients. Cardiac biomarkers troponin and brain natriuretic peptide (BNP) were raised in almost 90% and 87% of patients, respectively. Electrocardiogram findings were nonspecific and included ST-segment and T-wave changes. Echocardiogram commonly showed left ventricular systolic dysfunction with increased heart size. Cardiac magnetic resonance imaging (CMRI) exhibited myocardial edema and injury. The most prevalent histopathological feature appreciated was diffuse lymphocytic inflammatory infiltrates. Antivirals and corticosteroids were the most frequently used medications. About 38% of patients also needed vasopressor assistance. Out of 42 patients, 67% recovered, and eight died.
CONCLUSION
CONCLUSIONS
Because of the risk of a sudden worsening of patients conditions and myocarditis association with considerable mortality and morbidity, a knowledge of this cardiac complication of Covid-19 disease is crucial for healthcare professionals.
Types de publication
Case Reports
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14470Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733. https://doi.org/10.1056/NEJMoa2001017
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802-810. https://doi.org/10.1001/jamacardio.2020.0950
Zou F, Qian Z, Wang Y, Zhao Y, Bai J. Cardiac Injury and COVID-19: a systematic review and meta-analysis. CJC Open. 2020;2:386-394. https://doi.org/10.1016/j.cjco.2020.06.010
Trachtenberg BH, Hare JM. Inflammatory cardiomyopathic syndromes. Circ Res. 2017;121:803-818. https://doi.org/10.1161/CIRCRESAHA.117.310221
Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379:738-747. https://doi.org/10.1016/S0140-6736(11)60648-X
Shauer A, Gotsman I, Keren A, et al. Acute viral myocarditis: current concepts in diagnosis and treatment. Isr Med Assoc J. 2013;15:180-185.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23:60-63. https://doi.org/10.1136/bmjebm-2017-110853
Cizgici AY, Zencirkiran Agus H, Yildiz M. COVID-19 myopericarditis: it should be kept in mind in today's conditions. Am J Emerg Med. 2020;38:1547.e5-1547.e6. https://doi.org/10.1016/j.ajem.2020.04.080
Hussain H, Fadel A, Alwaeli H, Guardiola V. Coronavirus (COVID-19) fulminant myopericarditis and acute respiratory distress syndrome (ARDS) in a middle-aged male patient. Cureus. 2020;12:e8808. https://doi.org/10.7759/cureus.8808
Coyle J, Igbinomwanhia E, Sanchez-Nadales A, Danciu S, Chu C, Shah N. A recovered case of COVID-19 myocarditis and ARDS treated with corticosteroids, tocilizumab, and experimental AT-001. JACC Case Rep. 2020;2:1331-1336. https://doi.org/10.1016/j.jaccas.2020.04.025
Auer J, Neuhierl F, Hetzmann Z. COVID-19-related fatal myocarditis in a 42-year-old female patient. Cardiol J. 2020;27:642-643. https://doi.org/10.5603/CJ.2020.0155
Dabbagh MF, Aurora L, D'Souza P, Weinmann AJ, Bhargava P, Basir MB. Cardiac tamponade secondary to COVID-19. JACC Case Rep. 2020;2:1326-1330. https://doi.org/10.1016/j.jaccas.2020.04.009
Nicol M, Cacoub L, Baudet M, et al. Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome. ESC Heart Fail. 2020;7(6):4371-4376. https://doi.org/10.1002/ehf2.13047
Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2021:42:191. https://doi.org/10.1093/eurheartj/ehaa190
Oberweis ML, Codreanu A, Boehm W, et al. Pediatric life-threatening coronavirus disease 2019 with myocarditis. Pediatr Infect Dis J. 2020;39:e147-e149. https://doi.org/10.1097/INF.0000000000002744
Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:819-824. https://doi.org/10.1001/jamacardio.2020.1096
Irabien-Ortiz Á, Carreras-Mora J, Sionis A, Pàmies J, Montiel J, Tauron M. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol. 2020;73:503-504. https://doi.org/10.1016/j.rec.2020.04.005
Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41:1861-1862. https://doi.org/10.1093/eurheartj/ehaa286
Rehman M, Gondal A, Rehman NU. Atypical manifestation of COVID-19-induced myocarditis. Cureus. 2020;12:e8685. https://doi.org/10.7759/cureus.8685
Kim IC, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J. 2020;41:1859. https://doi.org/10.1093/eurheartj/ehaa288
Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020;48:773-777. https://doi.org/10.1007/s15010-020-01424-5
Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report. Chest. 2020;158:e15-e19. https://doi.org/10.1016/j.chest.2020.04.024
Yuan WF, Tang X, Zhao XX. An 'asymptomatic' driver with COVID-19: atypical suspected myocarditis by SARS-CoV-2. Cardiovasc Diagn Ther. 2020;10:242-243. https://doi.org/10.21037/cdt.2020.03.08
Pavon AG, Meier D, Samim D, et al. First documentation of persistent SARS-Cov-2 infection presenting with late acute severe myocarditis. Can J Cardiol. 2020;36:1326.e5-1326.e7. https://doi.org/10.1016/j.cjca.2020.06.005
Juusela A, Nazir M, Gimovsky M. Two cases of coronavirus 2019-related cardiomyopathy in pregnancy. Am J Obstet Gynecol MFM. 2020;2:100113. https://doi.org/10.1016/j.ajogmf.2020.100113
Beşler MS, Arslan H. Acute myocarditis associated with COVID-19 infection. Am J Emerg Med. 2020;38:2489.e1-2489.e2. https://doi.org/10.1016/j.ajem.2020.05.100
Sardari A, Tabarsi P, Borhany H, Mohiaddin R, Houshmand G. Myocarditis detected after COVID-19 recovery. Eur Heart J Cardiovasc Imaging. 2021;22:131-132. https://doi.org/10.1093/ehjci/jeaa166
Trogen B, Gonzalez FJ, Shust GF. COVID-19-associated myocarditis in an adolescent. Pediatr Infect Dis J. 2020;39:e204-e205. https://doi.org/10.1097/INF.0000000000002788
Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22:911-915. https://doi.org/10.1002/ejhf.1828
Luetkens JA, Isaak A, Zimmer S, et al. Diffuse myocardial inflammation in COVID-19 associated myocarditis detected by multiparametric cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2020;13:e010897. https://doi.org/10.1161/CIRCIMAGING.120.010897
Kesici S, Aykan HH, Orhan D, Bayrakci B. Fulminant COVID-19-related myocarditis in an infant. Eur Heart J. 2020;41:3021. https://doi.org/10.1093/eurheartj/ehaa515
Hua A, O'Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020;41:2130. https://doi.org/10.1093/eurheartj/ehaa253
Yokoo P, Fonseca EKUN, Sasdelli Neto R, et al. COVID-19 myocarditis: a case report. Einstein. 2020;18:eRC5876. https://doi.org/10.31744/einstein_journal/2020RC5876
Khatri A, Wallach F. Coronavirus disease 2019 (Covid-19) presenting as purulent fulminant myopericarditis and cardiac tamponade: a case report and literature review. Heart Lung. 2020;49:858-863. https://doi.org/10.1016/j.hrtlng.2020.06.003
De Vita S, Ippolito S, Caracciolo MM, Barosi A. Peripartum cardiomyopathy in a COVID-19-infected woman: differential diagnosis with acute myocarditis-a case report from a Hub Institution during the COVID-19 outbreak. Echocardiography. 2020;37:1673-1677. https://doi.org/10.1111/echo.14873
Gnecchi M, Moretti F, Bassi EM, et al. Myocarditis in a 16-year-old boy positive for SARS-CoV-2. Lancet. 2020;395:e116. https://doi.org/10.1016/S0140-6736(20)31307-6
Fischer Q, Brillat-Savarin N, Ducrocq G, Ou P. Case report of an isolated myocarditis due to COVID-19 infection in a paediatric patient. Eur Heart J Case Rep. 2020;4(FI1):1-5. https://doi.org/10.1093/ehjcr/ytaa180
Dalen H, Holte E, Guldal AU, et al. Acute perimyocarditis with cardiac tamponade in COVID-19 infection without respiratory disease. BMJ Case Rep. 2020;13:e236218. https://doi.org/10.1136/bcr-2020-236218
Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020;395:1516. https://doi.org/10.1016/S0140-6736(20)30912-0
Spano G, Fischer K, Maillat C, Vicario G, Huber AT, Gräni C. Delayed isolated peri-myocarditis in a Covid-19 patient with respiratory symptoms but without lung involvement. Int J Cardiovasc Imaging. 2020;36:2279-2280. https://doi.org/10.1007/s10554-020-01943-0
Khalid Y, Dasu N, Dasu K. A case of novel coronavirus (COVID-19)-induced viral myocarditis mimicking a Takotsubo cardiomyopathy. HeartRhythm Case Rep. 2020;6:473-476. https://doi.org/10.1016/j.hrcr.2020.05.020
Giacomet V, Manfredini VA, Meraviglia G, et al. Acute inflammation and elevated cardiac markers in a two-month-old infant with severe acute respiratory syndrome coronavirus 2 infection presenting with cardiac symptoms. Pediatr Infect Dis J. 2020;39:e149-e151. https://doi.org/10.1097/INF.0000000000002750
Warchoł I, Dębska-Kozłowska A, Karcz-Socha I, Książczyk M, Szymańska K, Lubiński A. Terra incognita: clinically suspected myocarditis in a patient with severe acute respiratory syndrome coronavirus 2 infection. Pol Arch Intern Med. 2020;130:446-448. https://doi.org/10.20452/pamw.15309
Craver R, Huber S, Sandomirsky M, McKenna D, Schieffelin J, Finger L. Fatal eosinophilic myocarditis in a healthy 17-year-old male with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2c). Fetal Pediatr Pathol. 2020;39:263-268. https://doi.org/10.1080/15513815.2020.1761491
Chiu JS, Lahoud-Rahme M, Schaffer D, Cohen A, Samuels-Kalow M. Kawasaki disease features and myocarditis in a patient with COVID-19. Pediatr Cardiol. 2020;41(7):1526-1528. https://doi.org/10.1007/s00246-020-02393-0
Singhavi R, Sharma K, Desai HD, Patel R, Jadeja D. A case of hemolytic anemia with acute myocarditis and cardiogenic shock: a rare presentation of COVID-19. Cureus. 2020;12:e10657. https://doi.org/10.7759/cureus.10657
Garot J, Amour J, Pezel T, et al. SARS-CoV-2 fulminant myocarditis. JACC Case Rep. 2020;2:1342-1346. https://doi.org/10.1016/j.jaccas.2020.05.060
El-Assaad I, Hood-Pishchany MI, Kheir J, et al. Complete heart block, severe ventricular dysfunction, and myocardial inflammation in a child with COVID-19 infection. JACC Case Rep. 2020;2:1351-1355. https://doi.org/10.1016/j.jaccas.2020.05.023
Salehi F, Patel N, Sayegh G, et al. COVID-19 in hypertensive patients: a review of comorbidities and worse outcomes. Eur J Biomed Pharm Sci. 2021;8:01-03. https://doi.org/10.17605/OSF.IO/ZFTW9
Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021;75:e13746. https://doi.org/10.1111/ijcp.13746
Menon T, Sharma R, Kataria S, et al. The association of acute kidney injury with disease severity and mortality in COVID-19: a systematic review and meta-analysis. Cureus. 2021;13:e13894. https://doi.org/10.7759/cureus.13894
Singh R, Rathore SS, Khan H, et al. Mortality and severity in COVID-19 patients on ACEIs & ARBs - a meta-regression analysis. medRxiv. 2021. https://doi.org/10.1101/2021.03.14.21253557
Bansal V, Mahapure KS, Mehra I, et al. Mortality benefit of convalescent plasma in COVID-19: a systematic review and meta-analysis. Front Med. 2021;8:624924. https://doi.org/10.3389/fmed.2021.624924
Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811-818. https://doi.org/10.1001/jamacardio.2020.1017
Rav-Acha M, Orlev A, Itzhaki I, et al. Cardiac arrhythmias amongst hospitalised Coronavirus 2019 (COVID-19) patients: prevalence, characterisation, and clinical algorithm to classify arrhythmic risk. Int J Clin Pract. 2021;75:e13788. https://doi.org/10.1111/ijcp.13788
Nieminen MS, Heikkilä J, Karjalainen J. Echocardiography in acute infectious myocarditis: relation to clinical and electrocardiographic findings. Am J Cardiol. 1984;53:1331-1337. https://doi.org/10.1016/0002-9149(84)90089-4
Matshela MR. The role of echocardiography in acute viral myocarditis. Cardiovasc J Afr. 2019;30:239-244. https://doi.org/10.5830/CVJA-2018-069
Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol. 2000;36:227-232. https://doi.org/10.1016/s0735-1097(00)00690-2
Weckbach LT, Curta A, Bieber S, et al. Myocardial inflammation and dysfunction in COVID-19-associated myocardial injury. Circ Cardiovasc Imaging. 2021;14:11713. https://doi.org/10.1161/CIRCIMAGING.120.011713
Bieber S, Kraechan A, Hellmuth JC, et al. Left and right ventricular dysfunction in patients with COVID-19-associated myocardial injury. Infection. 2021;49:491-500. https://doi.org/10.1007/s15010-020-01572-8
Abdel-Aty H, Boyé P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45:1815-1822. https://doi.org/10.1016/j.jacc.2004.11.069
Friedrich MG, Sechtem U, Schulz-Menger J, et al. International consensus group on cardiovascular magnetic resonance in myocarditis. cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53:1475-1487. https://doi.org/10.1016/j.jacc.2009.02.007
Han Y, Chen T, Bryant J, et al. Society for cardiovascular magnetic resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic. J Cardiovasc Magn Reson. 2020;22:26. https://doi.org/10.1186/s12968-020-00628-w
Page EM, Ariëns RAS. Mechanisms of thrombosis and cardiovascular complications in COVID-19. Thromb Res. 2021;200:1-8. https://doi.org/10.1016/j.thromres.2021.01.005
Singh R, Rathore SS, Khan H, et al. Association of obesity with COVID-19 severity and mortality. A systemic review and meta-regression. medRxiv. 2021. https://doi.org/10.1101/2021.05.08.21256845
Zhou Y, Fu B, Zheng X, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 2020;7:998-1002. https://doi.org/10.1093/nsr/nwaa041
Shams S, Rathore SS, Anvekar P, et al. Maculopapular skin eruptions associated with Covid-19: a systematic review. Dermatol Ther. 2021;34:e14788. https://doi.org/10.1111/dth.14788
Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41:1798-1800. https://doi.org/10.1093/eurheartj/ehaa231
Li L, Hill J, Spratt JC, Jin Z. Myocardial injury in severe COVID-19: identification and management. Resuscitation. 2021;160:16-17. https://doi.org/10.1016/j.resuscitation.2020.11.040
Ali A, Krishnamoorthy S, John Reng G, et al. Covid-19 and acute coronary syndrome (ACS): a review of its pathophysiology, prevalence and management during the pandemic. Arch Int Med Res. 2021;4:66-76. https://doi.org/10.26502/aimr.0058
Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5
Ali A, Krishnamoorthy S, Reng GJ, et al. Covid-19 and acute coronary syndrome (ACS): a review of its pathophysiology, prevalence and management during the pandemic. Arch Intern Med Res. 2021;4:66-76.
Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9:45. https://doi.org/10.1186/s40249-020-00662-x
Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39:618-625. https://doi.org/10.1111/j.1365-2362.2009.02153.x
Nicin L, Abplanalp WT, Mellentin H, et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J. 2020;41:1804-1806. https://doi.org/10.1093/eurheartj/ehaa311
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069. https://doi.org/10.1001/jama.2020.1585
Del Sole F, Farcomeni A, Loffredo L, et al. Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50:e13378. https://doi.org/10.1111/eci.13378
Pellegrini D, Kawakami R, Guagliumi G, et al. Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study. Circulation. 2021;143:1031-1042. https://doi.org/10.1161/CIRCULATIONAHA.120.051828
Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;19:101-115. https://doi.org/10.1016/j.thromres.2020.06.029
van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24:696. https://doi.org/10.1186/s13054-020-03400-9
Hosseinzadeh MH, Shamshirian A, Ebrahimzadeh MA. Dexamethasone vs COVID-19: an experimental study in line with the preliminary findings of a large trial. Int J Clin Pract. 2021;75:e13943. https://doi.org/10.1111/ijcp.13943
EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation. https://www.ema.europa.eu/en/news/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-mechanical-ventilation#:~:text=EMA's%20human%20medicines%20committee%20. Accessed January 9, 2021.
RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020;384:693-704.
Office of the Commissioner. FDA approves first treatment for COVID-19. Fda.gov. Published 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. Accessed January 9, 2021.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813-1826. https://doi.org/10.1056/NEJMoa2007764
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048-1057. https://doi.org/10.1001/jama.2020.16349
Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Resp Med. 2021;9:196-206. https://doi.org/10.1016/S2213-2600(20)30511-7
Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795-807. https://doi.org/10.1056/NEJMoa2031994
The REMAP-CAP Investigators, Gordon AC. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 - preliminary report. N Engl J Med. 384:1491-1502. https://doi.org/10.1101/2021.01.07.21249390